SurModics (SRDX) Tops Q4 EPS by 11c; Approves Additional $20M Stock Buyback

Go back to SurModics (SRDX) Tops Q4 EPS by 11c; Approves Additional $20M Stock Buyback

SurModics Reports Fourth Quarter Fiscal 2015 Results

November 10, 2015 7:35 AM EST

GAAP Revenue Growth of 13% to $17.4 Million and GAAP EPS of $0.22 Non-GAAP Revenue Up 8% and Non-GAAP EPS of $0.30 FDA IDE Approval for Early Feasibility Study of the SurVeil Drug-Coated Balloon Increase in Share Repurchase Authorization to $30.0 Million Fiscal 2016 Guidance Outlined

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2015 fourth... More